HB DÜSSELDORF. In addition to the increasing demand of the cosmetics industry was mainly the pharmaceutical business with insulin pens , syringes and inhalers for Gerresheimer the tills ringing . "The third quarter has performed very well and makes us hopeful , "said the acting CEO since June Uwe Röhrhoff on Wednesday in a conference call. He reiterated full-year forecast and announced the resumption of dividend payment. 20 to 30 percent of net income to be distributed .
Last year, the shareholders were left empty-handed after a turnover and profit decline. During the economic crisis pharmaceutical customers had reduced their huge inventories. The business with the pharmaceutical industry makes up about 80 percent for Gerresheimer .
In the coming years will Röhrhoff promote international business. The greatest potential he sees in South America , China and Russia. Revenue is expected to double in these regions during the three years to 200 million euros. The backlog in the countries to offer medical care in the business with the pharmaceutical industry, enormous potential. However, the Rheinmetall Group will not only grow organically, but is also potential takeover targets , with sales of up to € 50 million targeted.
In June to August , sales – adjusted for the sales field of technical plastic systems – by 9.5 percent to 259.4 million euros. Net earned the company 14.1 million versus a loss of four million euros a year earlier. Analysts had expected only with ten million. For the fiscal year ending in November is a revenue increase of three to four per cent (2009: EUR 1.0 billion ) and is an operating margin (EBITDA margin ) of 19.5 to 20 ( 19.2 percent).
On the stock market got the news well: The shares marked time with a premium of two percent to 30.38 euros , a new annual high. Thus , the MDAX title since early September, about ten percent gained in value .